What the trials measured
Two published trials sit behind the figures used on this site. One tested the drug on its own; the other tested it alongside structured lifestyle coaching.
- Who took part:
- 1,742 adults with obesity, or overweight with weight-related conditions
- How long:
- 56 weeks
- Compared with:
- Placebo
- Average weight loss:
- 6.1% at the full 32/360 mg dose (placebo 1.3%)
- Lost at least 5%:
- 48% of participants (placebo 16%)
- Who took part:
- Adults with obesity taking the drug alongside intensive behavioural modification
- How long:
- 56 weeks
- Compared with:
- Placebo plus the same intensive behaviour therapy
- Average weight loss:
- 9.3% with the drug, 5.1% with therapy alone
- What it shows:
- Combining the medication with structured lifestyle change added to the result
What the averages look like in pounds
Averages from trial data. Individual results vary, but these give you a realistic picture of what to expect.
| Time | % of body weight | 200 lb person | 250 lb person |
|---|---|---|---|
| 56 weeks (COR-I) | 6.1% average | ~12 lbs | ~15 lbs |
| 56 weeks with behaviour therapy (COR-BMOD) | 9.3% average | ~19 lbs | ~23 lbs |
The four phases of the year
Knowing where you are in the arc helps you manage expectations — and stops you from panicking when the scale stalls.
Four-week dose step-up
- The dose is titrated up to 32/360 mg per day over the first four weeks
- Nausea was the most common side effect in trials, at about 1 in 3 participants
- The tablets are extended-release and taken twice daily
Appetite and craving changes
- Appetite and craving changes are typically noticed within 4–8 weeks
- The drug acts on brain reward and craving pathways rather than only on fullness
- The full daily dose has usually been reached by this point
Significant weight loss
- Significant weight loss is typically seen by 16–24 weeks
- COR-I measured its headline 6.1% average at 56 weeks, not at this point
- About half of COR-I participants had lost at least 5% by the end of the trial
Staying on treatment
- COR-BMOD suggests structured lifestyle support adds to what the drug does on its own
- Weight regain after stopping is expected
- The drug has to be tapered — stopping abruptly can cause withdrawal from the bupropion component
The first month: managing expectations
A four-week step-up before the full dose
Contrave is titrated to its full 32/360 mg daily dose over the first four weeks. Appetite and craving changes are typically noticed within 4–8 weeks, so the first month is mostly about getting onto the dose and through the nausea, which about 1 in 3 trial participants reported.
Significant weight loss is typically seen by 16–24 weeks. The 6.1% average from COR-I was measured at 56 weeks, so month-one numbers will be much smaller than the headline figure.
Stopping Contrave
This one has to be tapered
Weight regain after stopping is expected. Contrave also has to be tapered rather than stopped abruptly, because stopping suddenly can cause withdrawal from the bupropion component. If you are thinking about coming off it, plan that with your prescriber rather than simply stopping.
Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Clinical trial data for Naltrexone / Bupropion ER
Weight loss figures come from the COR-I trial (1,742 adults, 56 weeks, The Lancet 2010) and COR-BMOD (56 weeks, Obesity 2011). Pound conversions are calculated from the trial percentages at 200 lb and 250 lb starting weights.
- COR-I — Naltrexone / Bupropion: 1,742 adults with obesity or overweight with comorbidities, 56 weeks. The Lancet, 2010. View source ↗
- COR-BMOD — Naltrexone / Bupropion: Adults with obesity, with intensive behaviour therapy, 56 weeks. Obesity, 2011. View source ↗
Keep reading
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: